Development of Early-Stage Bispecific T-Cell Engager AMG 794 for Solid Tumors discontinued
“Amgen on Monday terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer. In an update to the clinicaltrials.gov website, the company noted that it “made the business decision to discontinue development of AMG 794” while maintaining that “the safety profile of AMG 794 remains unchanged.” In line with the discontinuation of AMG 794, Amgen will also stop the Phase I study which was assessing the safety and tolerability of the bispecific T cell engager in several malignant solid tumor indications.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.